Serial 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)

Jennifer M. Specht, Stephen L. Tam, Brenda F. Kurland, Julie R. Gralow, Robert B Livingston, Hannah M. Linden, Georgiana K. Ellis, Erin K. Schubert, Lisa K. Dunnwald, David A. Mankoff

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Background: The response of bone-dominant (BD) breast cancer to therapy is difficult to assess by conventional imaging. Our preliminary studies have shown that quantitative serial 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography (FDG PET) correlates with therapeutic response of BD breast cancer, but the relationship to long-term outcome measures is unknown. Our goal was to evaluate the prognostic power of serial FDG PET in BD breast cancer patients undergoing treatment. Methods: We reviewed medical records of 405 consecutive breast cancer patients referred for FDG PET. Of these, 28 demonstrated metastatic BD breast cancer, were undergoing treatment, had at least 2 serial PET scans, and had abnormal FDG uptake on the first scan. Standardized uptake value (SUV) for the most conspicuous bone lesion at the initial scan, absolute change in SUV over an interval of 1-17 months, and percent change in SUV were considered as predictors of time-to-progression (TTP) and time to skeletal-related event (t-SRE). Results: Using proportional hazards regression, smaller percentage decreases in SUV (or increases in SUV) were associated with a shorter TTP (P < 0.006). A patient with no change in SUV was twice as likely to progress compared to a patient with a 42% median decrease in SUV. A higher SUV on the initial FDG PET predicted a shorter t-SRE (hazard ratio = 1.30, P < 0.02). Conclusions: Changes in serial FDG PET may predict TTP in BD metastatic breast cancer patients. However, larger prospective trials are needed to validate changes in FDG PET as a surrogate endpoint for treatment response.

Original languageEnglish (US)
Pages (from-to)87-94
Number of pages8
JournalBreast Cancer Research and Treatment
Volume105
Issue number1
DOIs
StatePublished - Sep 2007
Externally publishedYes

Fingerprint

Positron-Emission Tomography
Breast Neoplasms
Bone and Bones
Glucose
Therapeutics
Medical Records
Biomarkers
Outcome Assessment (Health Care)

Keywords

  • Bone-dominant breast cancer
  • FDG-PET imaging
  • Metastatic breast cancer
  • Monitoring treatment response
  • Skeletal-related events
  • Time to progression

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Serial 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). / Specht, Jennifer M.; Tam, Stephen L.; Kurland, Brenda F.; Gralow, Julie R.; Livingston, Robert B; Linden, Hannah M.; Ellis, Georgiana K.; Schubert, Erin K.; Dunnwald, Lisa K.; Mankoff, David A.

In: Breast Cancer Research and Treatment, Vol. 105, No. 1, 09.2007, p. 87-94.

Research output: Contribution to journalArticle

Specht, Jennifer M. ; Tam, Stephen L. ; Kurland, Brenda F. ; Gralow, Julie R. ; Livingston, Robert B ; Linden, Hannah M. ; Ellis, Georgiana K. ; Schubert, Erin K. ; Dunnwald, Lisa K. ; Mankoff, David A. / Serial 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). In: Breast Cancer Research and Treatment. 2007 ; Vol. 105, No. 1. pp. 87-94.
@article{3da7db0b031c4077aa936a0f3778fc3f,
title = "Serial 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)",
abstract = "Background: The response of bone-dominant (BD) breast cancer to therapy is difficult to assess by conventional imaging. Our preliminary studies have shown that quantitative serial 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography (FDG PET) correlates with therapeutic response of BD breast cancer, but the relationship to long-term outcome measures is unknown. Our goal was to evaluate the prognostic power of serial FDG PET in BD breast cancer patients undergoing treatment. Methods: We reviewed medical records of 405 consecutive breast cancer patients referred for FDG PET. Of these, 28 demonstrated metastatic BD breast cancer, were undergoing treatment, had at least 2 serial PET scans, and had abnormal FDG uptake on the first scan. Standardized uptake value (SUV) for the most conspicuous bone lesion at the initial scan, absolute change in SUV over an interval of 1-17 months, and percent change in SUV were considered as predictors of time-to-progression (TTP) and time to skeletal-related event (t-SRE). Results: Using proportional hazards regression, smaller percentage decreases in SUV (or increases in SUV) were associated with a shorter TTP (P < 0.006). A patient with no change in SUV was twice as likely to progress compared to a patient with a 42{\%} median decrease in SUV. A higher SUV on the initial FDG PET predicted a shorter t-SRE (hazard ratio = 1.30, P < 0.02). Conclusions: Changes in serial FDG PET may predict TTP in BD metastatic breast cancer patients. However, larger prospective trials are needed to validate changes in FDG PET as a surrogate endpoint for treatment response.",
keywords = "Bone-dominant breast cancer, FDG-PET imaging, Metastatic breast cancer, Monitoring treatment response, Skeletal-related events, Time to progression",
author = "Specht, {Jennifer M.} and Tam, {Stephen L.} and Kurland, {Brenda F.} and Gralow, {Julie R.} and Livingston, {Robert B} and Linden, {Hannah M.} and Ellis, {Georgiana K.} and Schubert, {Erin K.} and Dunnwald, {Lisa K.} and Mankoff, {David A.}",
year = "2007",
month = "9",
doi = "10.1007/s10549-006-9435-1",
language = "English (US)",
volume = "105",
pages = "87--94",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Serial 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)

AU - Specht, Jennifer M.

AU - Tam, Stephen L.

AU - Kurland, Brenda F.

AU - Gralow, Julie R.

AU - Livingston, Robert B

AU - Linden, Hannah M.

AU - Ellis, Georgiana K.

AU - Schubert, Erin K.

AU - Dunnwald, Lisa K.

AU - Mankoff, David A.

PY - 2007/9

Y1 - 2007/9

N2 - Background: The response of bone-dominant (BD) breast cancer to therapy is difficult to assess by conventional imaging. Our preliminary studies have shown that quantitative serial 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography (FDG PET) correlates with therapeutic response of BD breast cancer, but the relationship to long-term outcome measures is unknown. Our goal was to evaluate the prognostic power of serial FDG PET in BD breast cancer patients undergoing treatment. Methods: We reviewed medical records of 405 consecutive breast cancer patients referred for FDG PET. Of these, 28 demonstrated metastatic BD breast cancer, were undergoing treatment, had at least 2 serial PET scans, and had abnormal FDG uptake on the first scan. Standardized uptake value (SUV) for the most conspicuous bone lesion at the initial scan, absolute change in SUV over an interval of 1-17 months, and percent change in SUV were considered as predictors of time-to-progression (TTP) and time to skeletal-related event (t-SRE). Results: Using proportional hazards regression, smaller percentage decreases in SUV (or increases in SUV) were associated with a shorter TTP (P < 0.006). A patient with no change in SUV was twice as likely to progress compared to a patient with a 42% median decrease in SUV. A higher SUV on the initial FDG PET predicted a shorter t-SRE (hazard ratio = 1.30, P < 0.02). Conclusions: Changes in serial FDG PET may predict TTP in BD metastatic breast cancer patients. However, larger prospective trials are needed to validate changes in FDG PET as a surrogate endpoint for treatment response.

AB - Background: The response of bone-dominant (BD) breast cancer to therapy is difficult to assess by conventional imaging. Our preliminary studies have shown that quantitative serial 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography (FDG PET) correlates with therapeutic response of BD breast cancer, but the relationship to long-term outcome measures is unknown. Our goal was to evaluate the prognostic power of serial FDG PET in BD breast cancer patients undergoing treatment. Methods: We reviewed medical records of 405 consecutive breast cancer patients referred for FDG PET. Of these, 28 demonstrated metastatic BD breast cancer, were undergoing treatment, had at least 2 serial PET scans, and had abnormal FDG uptake on the first scan. Standardized uptake value (SUV) for the most conspicuous bone lesion at the initial scan, absolute change in SUV over an interval of 1-17 months, and percent change in SUV were considered as predictors of time-to-progression (TTP) and time to skeletal-related event (t-SRE). Results: Using proportional hazards regression, smaller percentage decreases in SUV (or increases in SUV) were associated with a shorter TTP (P < 0.006). A patient with no change in SUV was twice as likely to progress compared to a patient with a 42% median decrease in SUV. A higher SUV on the initial FDG PET predicted a shorter t-SRE (hazard ratio = 1.30, P < 0.02). Conclusions: Changes in serial FDG PET may predict TTP in BD metastatic breast cancer patients. However, larger prospective trials are needed to validate changes in FDG PET as a surrogate endpoint for treatment response.

KW - Bone-dominant breast cancer

KW - FDG-PET imaging

KW - Metastatic breast cancer

KW - Monitoring treatment response

KW - Skeletal-related events

KW - Time to progression

UR - http://www.scopus.com/inward/record.url?scp=34250331149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250331149&partnerID=8YFLogxK

U2 - 10.1007/s10549-006-9435-1

DO - 10.1007/s10549-006-9435-1

M3 - Article

C2 - 17268819

AN - SCOPUS:34250331149

VL - 105

SP - 87

EP - 94

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -